in 24 455 patients showed that the rates of recurrent VTE, fatal PE, and all-cause mortality were similar to the NOACs; however, the rate of major bleeding was significantly lower with the NOACs than with warfarin. 2,4 Due to convenience in use and no need for routine monitoring, the number of patients with VTE and atrial fibrillation (AF) who take NOACs increase worldwide. Recent data from the RIETE registry 5 showed that a nonnegligible proportion of VTE patients received nonrecommended doses and regimens of NOACs, which was associated with a higher rate INTRODUCTION Venous thromboembolism (VTE), defined as deep vein thrombosis (DVT) or pulmonary embolism (PE), occurs in about 1 in 1000 persons each year. 1,2 There is evidence that VTE is often asymptomatic, underdiagnosed, and undertreated. 3 For more than 60 years, vitamin K antagonists (VKAs) were the mainstay of VTE treatment. Non-vitamin K antagonist oral anticoagulants (NOACs) have altered the landscape of treatment options. A meta-analysis of the 5 phase III trials comparing 4 NOACs (rivaroxaban, dabigatran, apixaban, and edoxaban) with warfarin